Prophage vitespen: Updated Phase II data

Updated data from a single-arm, U.S. Phase II trial in 46 patients with newly diagnosed GMB showed that intradermal Prophage G-100 plus standard of care (SOC) radiation

Read the full 272 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE